Work

High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors

Year: 2020

Type: article

Study design: Observational Study

Source: American Journal of Ophthalmology

DOI: 10.1016/j.ajo.2020.07.031

Authors: Natalie Wolkow, Frederick A. Jakobiec, Amir H. Afrogheh, Sara I. Pai, William C. Faquin

Institutions: Massachusetts Eye and Ear Infirmary, Harvard University, National Health Laboratory Service, University of the Western Cape, Massachusetts General Hospital

Language: English

Topic: Ocular Oncology and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Massachusetts General Hospital, United States and Canadian Academy of Pathology, U.S. Food and Drug Administration, National Cancer Institute, National Institute of Dental and Craniofacial Research

Awards: G1819525301, G2450952232, G8756709032

OpenAlex ID: W3044153289

FWCI: 1.558

Cites: 41

Cited by: 16

Related to: 10